Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.08
BICX's Cash-to-Debt is ranked lower than
76% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 0.40 vs. BICX: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
BICX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.12 Max: No Debt
Current: 0.08
Equity-to-Asset -17.30
BICX's Equity-to-Asset is ranked lower than
100% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. BICX: -17.30 )
Ranked among companies with meaningful Equity-to-Asset only.
BICX' s Equity-to-Asset Range Over the Past 10 Years
Min: -17.3  Med: 0.05 Max: 0.77
Current: -17.3
-17.3
0.77
Piotroski F-Score: 2
Altman Z-Score: -93.74
Beneish M-Score: -16.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -310.83
BICX's Operating Margin % is ranked lower than
99% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. BICX: -310.83 )
Ranked among companies with meaningful Operating Margin % only.
BICX' s Operating Margin % Range Over the Past 10 Years
Min: -553.3  Med: -260.72 Max: -44.56
Current: -310.83
-553.3
-44.56
Net Margin % -841.17
BICX's Net Margin % is ranked lower than
100% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 4.84 vs. BICX: -841.17 )
Ranked among companies with meaningful Net Margin % only.
BICX' s Net Margin % Range Over the Past 10 Years
Min: -841.17  Med: -267.12 Max: -52.98
Current: -841.17
-841.17
-52.98
ROA % -675.94
BICX's ROA % is ranked lower than
100% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 4.66 vs. BICX: -675.94 )
Ranked among companies with meaningful ROA % only.
BICX' s ROA % Range Over the Past 10 Years
Min: -1550  Med: -166.67 Max: -18.07
Current: -675.94
-1550
-18.07
ROC (Joel Greenblatt) % -15785.71
BICX's ROC (Joel Greenblatt) % is ranked lower than
100% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. BICX: -15785.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BICX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -102360  Med: -16784.62 Max: -6254.55
Current: -15785.71
-102360
-6254.55
3-Year Revenue Growth Rate -12.60
BICX's 3-Year Revenue Growth Rate is ranked lower than
86% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. BICX: -12.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BICX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.75 Max: 14.5
Current: -12.6
0
14.5
3-Year EBITDA Growth Rate -13.40
BICX's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. BICX: -13.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BICX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.4 Max: 74.7
Current: -13.4
0
74.7
GuruFocus has detected 5 Warning Signs with BioCorRx Inc $BICX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BICX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BICX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621498    SIC: 8093
Compare:OTCPK:AMEH, NAS:JYNT, OTCPK:FCHS, OTCPK:ADPTQ, OTCPK:CCEL, OTCPK:ARPC, AMEX:AMS, OTCPK:CAMDF, OTCPK:BNKL, OTCPK:CVHIF, AMEX:SSY, OTCPK:JRSS, OTCPK:AGHEF, OTCPK:PFHO, AMEX:HH, OTCPK:WNDM, OTCPK:BRRZF, OTCPK:CATS, OTCPK:LMNK, OTCPK:QNIIF » details
Headquarter Location:USA
BioCorRx Inc is an alcohol treatment and rehabilitation company. It provides an alcoholism treatment program called BioCorRx Recovery Program, that empowers patients to succeed in their overall recovery.

Fresh Start Private Management, Inc., a Nevada corporation on January 28, 2008 as Cetrone Energy Company. On July 26, 2010, the Company changed its name to Fresh Start Private Management Inc. Through its wholly owned subsidiary, it is an alcohol rehabilitation and treatment center. The company was established in January 2010 and is currently operating in Santa Ana, California. Its alcohol rehabilitation program consists of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with life counseling sessions from specialized counselors. The Company operates within the Specialty Hospitals, Expert Psychiatric industry, specifically within the industry subsets of Alcoholism Rehabilitation Hospital. It has created an innovative alcohol treatment program that empowers patients to succeed in their overall recovery. The Company offers a treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends. It has been operating for approximately 36 months and has treated over 150 patients. Currently, it is treating about 2 to 3 patients per week. The alcohol treatment services costs an average of $49,300 per patient and is typically covered by insurance. The Company faces competition with the other rehabilitation service providers.

Top Ranked Articles about BioCorRx Inc

Private Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx Alpine Creek has completed its equity financing of addiction treatment company offering a unique approach to the treatment of substance abuse addiction
Private equity firm Alpine Creek has completed its equity financing of BioCorRx Inc. (BICX), an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. Read more...
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/3-24-17-smallcapvoice-interview-with-biocorrx-inc-bicx.
Brady Granier and Lourdes Felix called in to SmallCapVoice.com, Inc. to go over the exciting recent news for the Company. BICX recently announced it moved up to the OTCQB, their upcoming presentation at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29th, the positive preliminary data from preclinical studies evaluating BICX101, the validating work BICX is doing with the City of Anaheim to treat opioid and alcohol addiction, and more. "We are very happy with the way things are progressing with the company’s initiatives," stated Granier.  "This interview restates some of our most recent developments and we look forward to providing more updates in the future." About SmallCapVoice.com SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for their ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/.   About BioCorRx BioCorRx Inc. (BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com. Safe Harbor Statement The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
[email protected]
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304 
[email protected]

For SmallCapVoice.com
Stuart T. Smith
512-267-2430 
[email protected]

Read more...
America’s War on Drugs 'Forgotten people' are at greatest risk
President Donald Trump described them as America’s “forgotten people,” the less-educated white, middle-aged Americans. This group of individuals, together with the baby boomers and the so-called Generation X, are among the most vulnerable to heroin and prescription drug abuse. Several studies indicate that the number of drug overdose deaths among baby boomers, Generation X and less-educated white Americans has jumped in recent years. Read more...
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...
Alpine Creek and BioCorRx Announce Major Investment Into BioCorRx

SANTA ANA, CA--(Marketwired - Jun 20, 2016) - Alpine Creek Capital Partners ("Alpine Creek") and BioCorRx, Inc. (OTC PINK: BICX) ("BioCorRx" or "the Company") are pleased to announce an investment by Alpine Creek in the Company. The Company specializes in solutions for alcohol and opioid addiction treatment using its proprietary, non-addictive medication-assisted treatment (MAT) program called the BioCorRx® Recovery Program. The Company has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of an FDA-approved medicine, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant can significantly reduce cravings for alcohol or opioids for several months, depending on individual metabolism rates. In addition to the implant formulation, and perhaps more important, is the Company's comprehensive counseling program that was developed by addiction experts specific to individuals undergoing treatment with any form of sustained-release naltrexone. Travis Mullen, Managing Partner of Alpine Creek Capital Partners, said, "We couldn't be more excited about our investment in BioCorRx and the cutting edge program they have in place. The BioCorRx® Recovery Program which includes this naltrexone delivery system coupled with the tangible counseling program is literally saving lives and we look forward to arming as many families as possible with this amazing tool for their battle against alcohol or opioid addiction." The initial investment in the Company is $2,500,000 with an additional $2,500,000 expected within six months at the option of Alpine Creek. Details of the transaction can be found in the Company's filings with the Securities and Exchange Commission. In the coming weeks and months, the Company will announce its plans and initiatives for using the capital received from Alpine Creek. Brady Granier, CEO of BioCorRx, Inc., stated, "This is the single largest investment made in our company in its five plus years of existence. Since last year, Alpine has been a valued and trusted financial partner of BioCorRx and this transaction is a testament to the hard work that has been done by everyone in our company to create a product that we believe has great potential to combat this opioid epidemic, as well as the much larger alcoholism problem destroying families across the world. Our program and service model has evolved over the years into something we believe is truly unique and effective in battling addiction. With this significant partnership with Alpine, we will be able to start taking advantage of initiatives we have been dreaming about for years. The folks at Alpine are not your average investors. They really care about what we are doing and the impact it can make and they are also rolling up their sleeves and getting in the trenches along-side us to beat addiction." For more information on the BioCorRx® Recovery Program, please visit http://www.beataddiction.com or call 1-888-993-1099. About Alpine Creek Alpine Creek Capital Partners is a privately-funded investment firm focused on investing in the lower end of the middle-market. We focus on companies with annual revenues up to $50 million and a geographic footprint in the United States and Canada but we do not concentrate on any specific sector or industry. Instead our investment strategy is broad and opportunistic in nature with a strong preference toward investing alongside experienced management teams and industry veterans. With the understanding that every investment may not fit the traditional holding period, we are willing to take a longer-term growth partner approach with each investment. In doing so, we aim to provide more than just capital to our portfolio companies. By combining our team's financial, operational and mergers & acquisitions expertise with an extensive personal network of professional managers and industry specialists, Alpine Creek provides each portfolio company with a comprehensive suite of tools and resources to succeed. About BioCorRx Inc. BioCorRx, Inc. (OTC PINK: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, Naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx, Inc. is a one on one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long term naltrexone treatment. For more information on BICX, visit http://www.BioCorRx.com. Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.


Alpine Creek Contact:

Travis Mullen

Managing Partner

Alpine Creek Capital Partners

(949) 612-9203

[email protected]


Media Contact

Brady Granier

BioCorRx, Inc.

(714) 462-4884

[email protected]





Read more...

Ratios

vs
industry
vs
history
PS Ratio 57.50
BICX's PS Ratio is ranked lower than
100% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. BICX: 57.50 )
Ranked among companies with meaningful PS Ratio only.
BICX' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.15 Max: 185
Current: 57.5
0.95
185
EV-to-EBIT -12.67
BICX's EV-to-EBIT is ranked lower than
99.99% of the 292 Companies
in the Global Medical Care industry.

( Industry Median: 18.39 vs. BICX: -12.67 )
Ranked among companies with meaningful EV-to-EBIT only.
BICX' s EV-to-EBIT Range Over the Past 10 Years
Min: -180  Med: -5.9 Max: -0.7
Current: -12.67
-180
-0.7
EV-to-EBITDA -12.84
BICX's EV-to-EBITDA is ranked lower than
99.99% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 13.46 vs. BICX: -12.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
BICX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -180  Med: -6.3 Max: -0.7
Current: -12.84
-180
-0.7
Current Ratio 0.04
BICX's Current Ratio is ranked lower than
98% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. BICX: 0.04 )
Ranked among companies with meaningful Current Ratio only.
BICX' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.35 Max: 1
Current: 0.04
0.04
1
Quick Ratio 0.04
BICX's Quick Ratio is ranked lower than
98% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. BICX: 0.04 )
Ranked among companies with meaningful Quick Ratio only.
BICX' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.35 Max: 1
Current: 0.04
0.04
1
Days Sales Outstanding 33.80
BICX's Days Sales Outstanding is ranked higher than
56% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. BICX: 33.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
BICX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.05  Med: 160.29 Max: 452.04
Current: 33.8
11.05
452.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.20
BICX's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BICX: -10.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BICX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19  Med: -8.75 Max: 39.3
Current: -10.2
-19
39.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 11.50
BICX's Price-to-Median-PS-Value is ranked lower than
100% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. BICX: 11.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BICX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.5 Max: 11.5
Current: 11.5
0.2
11.5
Earnings Yield (Greenblatt) % -7.89
BICX's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 334 Companies
in the Global Medical Care industry.

( Industry Median: 4.98 vs. BICX: -7.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BICX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -32.19  Med: 0 Max: 0
Current: -7.89
-32.19
0

More Statistics

Revenue (TTM) (Mil) $0.70
EPS (TTM) $ -0.03
Beta-0.37
Short Percentage of Float0.00%
52-Week Range $0.01 - 0.34
Shares Outstanding (Mil)212.71
» More Articles for BICX

Headlines

Articles On GuruFocus.com
US Prisons Relying on Naltrexone to Treat Opioid Addiction Apr 10 2017 
Drug Addiction Treatment Should Start in Emergency Room Apr 04 2017 
Private Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx Apr 02 2017 
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc Mar 27 2017 
Majority of US Employers: Prescription Drug Misuse Is Grounds for Termination Mar 21 2017 
America’s War on Drugs Mar 07 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
ANGEL Program Gets National Attention Feb 13 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 

More From Other Websites
BioCorRx Submits Meeting Request for Pre-IND Meeting with FDA for BICX101 Apr 10 2017
BioCorRx Announces BICX101 Preclinical Update; ASAM Attendance Apr 05 2017
Private Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx Apr 02 2017
BioCorRx CEO Brady Granier Appears on Fox Business Network Mar 28 2017
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx... Mar 27 2017
BioCorRx Announces Upgrade to the OTCQB(R) Mar 22 2017
BioCorRx Announces Updates on Preclinical Studies of BICX101 and Pre-IND Meeting Request with FDA Mar 21 2017
BioCorRx to Present at the Sidoti & Company Spring 2017 Convention in NYC Mar 15 2017
BioCorRx Completes $940,000 Equity Financing and Announces Alpine Creek Capital has Agreed to Invest... Mar 10 2017
America's War on Drugs Mar 07 2017
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017
BioCorRx Provides Preclinical Study Update on BICX101 Development Feb 23 2017
Drug Addiction Treatment Stocks to Watch Feb 22 2017
BioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development Feb 21 2017
ANGEL Program Gets National Attention Feb 13 2017
BioCorRx Provides Business Update Webcast Feb 10 2017
BioCorRx to Collaborate with the City of Anaheim to Treat Opioid and Alcohol Addiction Feb 08 2017
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017
JGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of $0.09 Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)